Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7165471 | 0.98 | L3MBTL1 (0.68) | L3MBTL1RAB9AMAPTNPSR1LMNA | |
| SCHEMBL13202230 | 0.87 | L3MBTL1 (0.59) | L3MBTL1RAB9AMAPTNPSR1LMNA | |
| SCHEMBL399561 | 0.85 | L3MBTL1 (0.66) | L3MBTL1RAB9AMAPTNPSR1LMNA | |
| SCHEMBL14380436 | 0.85 | L3MBTL1 (0.53) | L3MBTL1RAB9AMAPTNPSR1LMNA | |
| SCHEMBL9443798 | 0.85 | L3MBTL1 (0.53) | L3MBTL1RAB9AMAPTNPSR1LMNA | |
| SCHEMBL568623 | 0.84 | L3MBTL1 (0.56) | L3MBTL1RAB9AMAPTNPSR1LMNA | |
| SCHEMBL29811663 | 0.84 | L3MBTL1 (0.56) | L3MBTL1RAB9AMAPTNPSR1LMNA | |
| SCHEMBL8935331 | 0.83 | L3MBTL1 (0.69) | L3MBTL1RAB9AMAPTNPSR1LMNA | |
| SCHEMBL2978238 | 0.83 | L3MBTL1 (1.00) | L3MBTL1RAB9AMAPTNPSR1LMNA | |
| SCHEMBL24749630 | 0.83 | L3MBTL1 (0.68) | L3MBTL1RAB9AMAPTNPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 558 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119390612-A | Preparation method and application of 1, 3-bis (2-methoxy-5- (trifluoromethyl) phenyl) urea | 上海泰坦科技股份有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-118373778-A | Preparation method of letromycin | 湖北广济医药科技有限公司 | 2024-07-23 | — | — | CN | claimed |
| CN-117658928-A | New preparation method of drug intermediate for preventing CMV infection | 北京康立生医药技术开发有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-114539085-B | Preparation of ureido derivatives | 山东诚创蓝海医药科技有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-113880776-B | Preparation method of rituximab intermediate | 山东诚创蓝海医药科技有限公司 | 2023-06-16 | — | — | CN | claimed |
| CN-115850192-A | Process for preparing 3,4-dihydroquinazoline derivatives | 南京正大天晴制药有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-115201377-A | Method for detecting migration quantity of 17 genotoxic aromatic amines in corn starch meal box food simulation liquid | 扬州市食品药品检验检测中心 | 2022-10-18 | — | — | CN | claimed |
| CN-114539085-A | Preparation of ureido derivative | 山东诚创蓝海医药科技有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-113880776-A | Preparation method of Latemozu intermediate | 山东诚创蓝海医药科技有限公司 | 2022-01-04 | — | — | CN | claimed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | claimed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| US-20260083721-A1 | 7-CYANO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO LTD (CN) | 2026-03-26 | — | — | US | disclosed |
| EP-4623914-A1 | USE OF 8-HYDROXYQUINOLINE DERIVATIVE | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| EP-0023100-A1 | Herbicidal compositions comprising a diphenyl ether compound in admixture with another herbicide | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-01-28 | — | — | EP | disclosed |
| EP-0002041-A1 | Processes for synthesizing bisazomethine-bisazo pigments | CIBA-GEIGY AG (CH) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | L3MBTL1 4176/4885RAB9A 1754/4885MAPT 281/4885 |
| US-20260083721-A1 | 7-CYANO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | HCCS, SLC38A7, HRAS | L3MBTL1 1152/4885RAB9A 2347/4885MAPT 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.